2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test
2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test